Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InspireMD (NSPR) Research & Development (2016 - 2025)

Historic Research & Development for InspireMD (NSPR) over the last 16 years, with Q3 2025 value amounting to $3.6 million.

  • InspireMD's Research & Development fell 715.2% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year increase of 2709.59%. This contributed to the annual value of $13.6 million for FY2024, which is 7083.07% up from last year.
  • Latest data reveals that InspireMD reported Research & Development of $3.6 million as of Q3 2025, which was down 715.2% from $3.8 million recorded in Q2 2025.
  • InspireMD's 5-year Research & Development high stood at $4.1 million for Q1 2025, and its period low was $839000.0 during Q1 2021.
  • Moreover, its 5-year median value for Research & Development was $2.1 million (2022), whereas its average is $2.4 million.
  • In the last 5 years, InspireMD's Research & Development skyrocketed by 19054.05% in 2021 and then crashed by 715.2% in 2025.
  • Quarter analysis of 5 years shows InspireMD's Research & Development stood at $1.5 million in 2021, then skyrocketed by 31.23% to $2.0 million in 2022, then grew by 1.09% to $2.0 million in 2023, then surged by 81.47% to $3.7 million in 2024, then fell by 1.57% to $3.6 million in 2025.
  • Its Research & Development was $3.6 million in Q3 2025, compared to $3.8 million in Q2 2025 and $4.1 million in Q1 2025.